Brokerages Set Capricor Therapeutics Inc (NASDAQ:CAPR) PT at $19.80

Capricor Therapeutics Inc (NASDAQ:CAPR) has been given a consensus recommendation of “Buy” by the five brokerages that are currently covering the firm, Marketbeat.com reports. Five investment analysts have rated the stock with a buy rating. The average 12-month target price among brokers that have covered the stock in the last year is $20.00.

A number of analysts have recently commented on CAPR shares. HC Wainwright restated a “buy” rating and set a $40.00 target price on shares of Capricor Therapeutics in a report on Tuesday. Maxim Group reissued a “buy” rating and set a $12.00 price objective on shares of Capricor Therapeutics in a research report on Tuesday. Finally, Oppenheimer upped their target price on shares of Capricor Therapeutics from $14.00 to $15.00 and gave the stock an “outperform” rating in a research note on Tuesday.

Capricor Therapeutics Stock Down 2.5 %

Shares of CAPR stock opened at $4.99 on Tuesday. The firm has a market capitalization of $159.58 million, a price-to-earnings ratio of -5.74 and a beta of 3.92. The stock has a fifty day moving average of $4.36 and a 200 day moving average of $5.18. Capricor Therapeutics has a 52 week low of $2.68 and a 52 week high of $7.28.

Capricor Therapeutics (NASDAQ:CAPR) last announced its earnings results on Wednesday, August 7th. The biotechnology company reported ($0.35) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.03). Capricor Therapeutics had a negative net margin of 102.93% and a negative return on equity of 220.27%. The company had revenue of $3.97 million for the quarter, compared to the consensus estimate of $4.51 million. Equities research analysts anticipate that Capricor Therapeutics will post -1.24 earnings per share for the current year.

Hedge Funds Weigh In On Capricor Therapeutics

A number of institutional investors have recently modified their holdings of CAPR. Marshall Wace LLP bought a new stake in Capricor Therapeutics during the 2nd quarter valued at $426,000. Renaissance Technologies LLC boosted its stake in Capricor Therapeutics by 158.7% in the second quarter. Renaissance Technologies LLC now owns 137,500 shares of the biotechnology company’s stock valued at $656,000 after acquiring an additional 84,350 shares in the last quarter. Main Street Financial Solutions LLC increased its position in shares of Capricor Therapeutics by 37.5% during the second quarter. Main Street Financial Solutions LLC now owns 27,500 shares of the biotechnology company’s stock worth $131,000 after purchasing an additional 7,500 shares in the last quarter. Rhumbline Advisers purchased a new stake in shares of Capricor Therapeutics in the 2nd quarter valued at about $147,000. Finally, Bank of New York Mellon Corp boosted its position in shares of Capricor Therapeutics by 12.8% in the 2nd quarter. Bank of New York Mellon Corp now owns 79,782 shares of the biotechnology company’s stock valued at $381,000 after purchasing an additional 9,040 shares during the period. 21.68% of the stock is owned by hedge funds and other institutional investors.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.